C5 and paroxysmal nocturnal hemoglobinuria: Danicopan, approved by the US FDA and the EMA in 2024, is the first oral add-on therapy (taken three times per day) to eculizumab or ravulizumab for patients with PNH and EVH receiving a C5 inhibitor [43,44].